Search

Displaying results 7421 - 7430 of 10000 in total
  1. Drug

    Orziloben

    go.drugbank.com/drugs/DB21653
    Experimental

    Orziloben is a small molecule drug. Orziloben has a monoisotopic molecular weight of 222.13 Da.

  2. Drug

    Tegeprotafib

    go.drugbank.com/drugs/DB21665
    Experimental

    Tegeprotafib is a small molecule drug. Tegeprotafib has a monoisotopic molecular weight of 326.04 Da.

  3. Drug

    Vamagloxistat

    go.drugbank.com/drugs/DB21666
    Experimental

    Vamagloxistat is a small molecule drug. Vamagloxistat has a monoisotopic molecular weight of 371.11 Da.

  4. Drug

    Milpecitinib

    go.drugbank.com/drugs/DB21676
    Experimental

    Milpecitinib is a small molecule drug. Milpecitinib has a monoisotopic molecular weight of 380.13 Da.

  5. Drug

    Claziprotamide

    go.drugbank.com/drugs/DB21687
    Experimental

    Claziprotamide is a small molecule drug. Claziprotamide has a monoisotopic molecular weight of 374.13 Da.

  6. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. … It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]

  7. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

    Synonyms: 3-hydroxy-O-phosphono-L-tyrosine
  8. Drug

    Tizaterkib

    go.drugbank.com/drugs/DB21296
    Investigational

    Tizaterkib has a monoisotopic molecular weight of 494.2 Da. … Tizaterkib is a small molecule drug. The usage of the INN stem '-terkib' in the name indicates that Tizaterkib is a extracellular signal-regulated kinase (ERK) inhibitor.

  9. Drug

    Rabies virus inactivated antigen, B

    go.drugbank.com/drugs/DB10062
    ApprovedInvestigational

    Inactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure prophylaxis against rabies.[L12795]

  10. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market … A phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness.